Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

Also called NCT04634916

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
  • C. R. Bard Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04634916
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04634916. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-26 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
Acronym
CONNECT-AV
Condition
Kidney Disease, End-Stage
Condition
End-stage Renal Disease
Condition
Arteriovenous Fistula
Intervention (Device)
EndoAVF Creation
Lead sponsor
C. R. Bard (class: industry)

Record details

Record id
cardio:ct-nct04634916
Content hash
757755114f2467c0919de83a220ae1b0e6e3721b191478aa145ccebc1d2621a3